PXK Inhibitors
Chemical inhibitors of PXK function by interfering with various signaling pathways and enzyme activities that PXK is associated with. Staurosporine and Bisindolylmaleimide operate by targeting protein kinases that PXK is known to interact with. Staurosporine is a broad-spectrum kinase inhibitor that disrupts kinase activity essential for PXK function in signal transduction pathways. Similarly, Bisindolylmaleimide specifically inhibits Protein Kinase C (PKC), and because PXK utilizes its PX domain to interact with PKC, this interaction is essential for PXK's role in transducing signals within the cell. The PI3K inhibitors LY294002 and Wortmannin obstruct the PI3K pathway, which is crucial for PXK's involvement in cellular signaling. Inhibiting PI3K leads to a cascade effect that ultimately disrupts PXK's functionality. PP2 and Dasatinib, which inhibit Src family tyrosine kinases and a broader range of tyrosine kinases, respectively, prevent phosphorylation events that PXK requires to function within signaling pathways.
Further, U0126, SP600125, and SB203580 inhibit various components of the MAPK pathway, such as MEK, JNK, and p38 MAPK. PXK's interaction with the MAPK pathway means that disruption of these kinases can lead to reduced signaling and thus diminished PXK activity. NF449, which targets the Gs-alpha subunit of G-proteins, disrupts G-protein-coupled signaling pathways that PXK is part of, leading to an inhibition of its role in these pathways. Go6983, another PKC inhibitor, like Bisindolylmaleimide, ensures that the interaction between PXK and PKC is inhibited, which is vital for PXK's function in signal transduction. Lastly, Y-27632 inhibits ROCK kinase, which impacts the actin cytoskeleton organization. Since PXK is implicated in cytoskeletal dynamics, inhibition of ROCK kinase by Y-27632 can lead to disrupted signaling pathways that PXK is involved in, thereby inhibiting its functional role in cellular processes.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. PXK, being a kinase-associated protein, requires kinase activity for its function. Staurosporine can inhibit the kinase activity that PXK is associated with, leading to a downstream inhibition of PXK's functionality in signal transduction pathways. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
Bisindolylmaleimide specifically inhibits Protein Kinase C (PKC). PXK interacts with PKC through its PX domain. Inhibition of PKC can therefore inhibit the interaction between PXK and other signaling molecules, thus inhibiting PXK's role in signal transduction. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of PI3K. PXK is known to interact with PI3K-related pathways. Inhibition of PI3K will disrupt the signaling cascade that PXK is part of, leading to an inhibition of PXK function in the cell. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is another potent inhibitor of PI3K. By inhibiting PI3K, the chemical will impede the phosphoinositide-dependent kinase pathways with which PXK is associated, leading to the functional inhibition of PXK. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family tyrosine kinases. PXK is involved in pathways that include tyrosine kinase signaling. By inhibiting Src kinases, PP2 could inhibit the phosphorylation events required for PXK function within its signaling pathways. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor. PXK functions in pathways that are regulated by tyrosine kinases. By inhibiting these kinases, Dasatinib can prevent the phosphorylation necessary for PXK's activity in signal transduction. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK, a kinase that lies upstream of ERK in the MAPK pathway. PXK, which may interact with components of the MAPK pathway, would have reduced function due to the inhibition of MEK, which would disrupt downstream signaling events involving PXK. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK, which is part of the MAPK pathway. PXK is associated with the MAPK pathway, and inhibiting JNK can lead to reduced signaling through PXK. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. PXK is implicated in MAPK pathway signaling. Inhibition of p38 MAPK can lead to diminished signaling through PXK, therefore inhibiting its function. | ||||||
NF449 | 627034-85-9 | sc-478179 sc-478179A sc-478179B | 10 mg 25 mg 100 mg | $203.00 $469.00 $1509.00 | 1 | |
NF449 is a potent and selective inhibitor of Gs-alpha subunit of G-proteins. PXK has been shown to interact with G-protein mediated signaling pathways. By inhibiting Gs-alpha, NF449 can disrupt the G-protein signaling that is essential for PXK function. | ||||||